Title of project or programme
Title of PINew Metal-Protein Attenuating Compounds with Neurotrophic Properties as a Therapeutic Strategy in Alzheimer’s Disease
Principal Investigators of project/programme grant
DrAdinaMichael-TitusUniversity of LondonUK
Address of institution of lead PI
InstitutionQueen Mary, University of London
Street AddressMile End Road
PostcodeE1 4NS
  • United Kingdom
Source of funding information
Total sum awarded (Euro)


Start date of award


Total duration of award in months


The project/programme is most relevant to
  • Alzheimer’s disease and other dementias
Research abstract in English

Alzheimer’s disease (AD) is the most common form of dementia, a devastating disease characterised by the loss of mental function. None of the drugs currently on the market affect significantly the disease. Anti-amyloid strategies are at the core of AD research, and it has been shown that Metal Protein-Attenuating Compounds (MPACs) which bind zinc and copper, reduce amyloid load and toxicity. Clinical trial results with MPACs which are quinoline compounds show excellent tolerability and improved cognition in AD patients and therefore show that MPACs are promising new AD drugs. Our project aims to further develop new substituted phosphonate MPACs, and facilitate the selection of a compound for Phase 1. Our proprietary non-quinoline MPAC compounds have additional and unique neurotrophic properties, which are particularly relevant in the context of AD, making these compounds better than the existing MPACs. The project will provide in vitro and in vivo efficacy data, safety, toxicity, metabolism and pharmacokinetic data, and thus facilitate the choice of a candidate compound for first studies in man.

Lay summary
In which category does this research fall?
  • Basic research

    Types: Investments > €500k
    Member States: United Kingdom
    Diseases: Alzheimer's disease & other dementias
    Years: 2011
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF